Elsevier

Urology

Volume 44, Issue 5, November 1994, Pages 732-736
Urology

Adult urology
Effect of yohimbine-trazodone on psychogenic impotence: A randomized, double-blind, placebo-controlled study

https://doi.org/10.1016/S0090-4295(94)80216-5Get rights and content

Abstract

Objectives.

The aim of this study was to determine the effectiveness and safety of yohimbine and trazodone used together for the treatment of pure psychogenic impotence.

Methods.

Sixty-three patients who had psychogenic impotence diagnosed on the basis of sexual history, results of physical examination, laboratory analysis, polysomnographic recording of nocturnal erections, and dynamic color Doppler sonography of the cavernosal arteries were entered into a randomized, double-blind, placebo-controlled, partial crossover study comparing placebo with yohimbine (15 mg per day orally) and trazodone (50 mg per day orally) used together. Treatment consisted of two 8-week courses. Patients who initially received placebo for 8 weeks were then switched to the 2-drug combination for 8 weeks. Erectile function, ejaculation, interest in sex, and sexual thoughts were investigated at the end of drug treatment and at 3- and 6-month follow-up. For statistical analysis chi-square, McNemar, and Student's t test for unpaired data were used.

Results.

Fifty-five patients (87%) completed the whole treatment schedule. Positiveclinical results (complete and partial responses) were obtained in 39 (71 %) patients at the end of the drug treatment phase. These results were significantly better than those obtained with placebo (p < 0.01). Positive results were maintained in 32 (58%) and 31 (56%) patients at 3- and 6-month follow-up, respectively. Minor drug-related adverse effects occurred in 6 (11 %) of the patients in the yohimbine-trazodone group and in 2 (4%) in the placebo group.

Conclusions.

The combination of yohimbine and trazodone is a safe and effective firstlinetreatment for psychogenic impotence.

Cited by (79)

  • Erectile Dysfunction

    2018, Integrative Medicine: Fourth Edition
  • Erectile Dysfunction

    2012, Integrative Medicine, Third Edition
  • Aphrodisiacs from plant and animal sources-A review of current scientific literature

    2011, Food Research International
    Citation Excerpt :

    Studies on Yohimbine investigated its effects on both psychogenic ED, caused by psychological complications, and organic ED, the inability to achieve or sustain erection due to physiological problems. The effect of Yohimbine on treatment of psychogenic erectile dysfunction has been well studied in randomized placebo-controlled trials, with results confirming its ability to treat erectile dysfunction (Mann et al., 1996; Montorsi et al., 1994; Reid et al., 1987; Vogt et al., 1997). Dosages of 15 mg–30 mg/day yohimbine were administered orally in the studies.

  • Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application

    2006, Pharmacology and Therapeutics
    Citation Excerpt :

    As mentioned above, the antagonist properties of mianserin and mirtazapine at α2-adrenergic receptors act in concert with their blockade of 5-HT2A/2C receptors to preserve sexual function in depression, and to oppose its perturbation in patients (both male and female) undergoing therapy with SSRIs (Aizenberg et al., 1997, 1999; Boyarsky et al., 1999; Farah, 1999; Gelenberg et al., 2000b; Waldinger et al., 2003). It is interesting to note that the combination of yohimbine with trazodone (which possesses 5-HT2C antagonist properties) achieved a marked reversal of psychogenic impotence (Montorsi et al., 1994). This finding further underscores interest in multi-target antidepressants combining antagonist properties at α2-adrenergic and 5-HT2A/2C receptors, yet devoid of the anti-histaminergic and anti-muscarinic actions of mirtazapine and mianserin (Section 9.4.2).

View all citing articles on Scopus
View full text